Cancer Research Technology appoints Deborah Harland as non-executive director
Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, has today announced the appointment of Dr Deborah Harland to its board of directors.
Deborah brings more than 25 years’ experience in the pharmaceutical sector and is currently a partner at SR One – the corporate venture capital arm of GlaxoSmithKline. In addition to her current role Deborah has held various roles spanning clinical development, medical affairs and business development throughout her career. She is currently a board member for several biotech companies in which SR One has invested including MISSION Therapeutics*.
Deborah succeeds Dr Ruth McKernan, who was appointed chief executive of Innovate UK earlier this year.
Dr Deborah Harland said: “I’m thrilled to join Cancer Research Technology at a time of exciting progress in our understanding of cancer and the development of vital new therapies for cancer patients.
“I look forward to contributing to CRT’s ambitious plans to drive delivery of the Cancer Research UK research strategy by identifying innovative scientific and business solutions to unmet needs in cancer.”
Dr Keith Blundy, Cancer Research Technology’s chief executive officer, said: “I’m delighted to welcome Deborah to Cancer Research Technology. She brings a wealth of experience in industrial drug discovery, licensing and venture financing.
“I have no doubt that CRT will benefit greatly from Deborah’s guidance and expertise as we continue our work to develop and advance discoveries that help beat cancer.”
For media enquiries please contact the Cancer Research Technology press office on 0203 469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
Notes to Editor
* MISSION Therapeutics was launched by CRT and the University of Cambridge in 2011 to build on Cancer Research UK-funded research into DNA damage repair. Deborah is also a board member of Asceneuron, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared, having previously sat on the board of several other firms.